Home › Christie Teigland

Christie Teigland, Ph.D.

Vice President, Research Science and Advanced Analytics

Christie Teigland, a woman with curly blonde hair, wearing a dark blazer and blue top, is smiling in front of a window with a blurred cityscape in the background. Christie Teigland, Ph.D., Vice President, Research Science and Advanced Analytics at Inovalon

Christie Teigland, Ph.D., is Vice President, Research Science and Advanced Analytics within Inovalon’s Insights Business Unit. She leads the design and implementation of studies focused on quality performance measure development and testing, health disparities and equity, predictive analytics, comparative effectiveness, health economics and outcomes research, and treatment pattern analyses.

Christie works with health plans, providers, and life sciences organizations to provide actionable real-world data insights. She serves as co-chair of the National Quality Forum (NQF) Scientific Methods Panel and is a member of the Pharmacy Quality Alliance (PQA) Quality Measure Expert Panel. She has served as principal investigator on numerous performance measure development projects, including several awarded by the National Committee on Quality Assurance (NCQA) for All-Cause 30-Day Readmissions and Potentially Avoidable Hospitalizations.

Prior to joining Inovalon, Christie specialized in quality and patient safety research at Leading Age New York, where she directed the development of innovative technology solutions to advance the use of electronic data-driven decision-making tools in long-term care settings.

Christie earned a Ph.D. in Economics and Econometric Forecasting from the University of New York at Albany and a Bachelor of Arts in Management Science and Economics from Moorhead State University.

Connect on LinkedIn

Authored Content

Cardiovascular

Real-World Adherence and Persistence Among U.S. Medicare Beneficiaries Initiating Advanced Lipid Lowering Therapies

Accepted for presentation at American Society for Preventive Cardiology 2026 Congress on CVD Prevention. Findings available upon request. Contact us for more information.

Fee-for-service medicare

Medicare Advantage vs. Traditional Fee-for-Service Medicare: Different Populations, Different Outcomes

Accepted for presentation at Academy of Managed Care Pharmacy. Findings available upon request. Contact us for more information.

Cardiovascular

Lipoprotein(a) Impact on Atherosclerotic Cardiovascular Disease and Major Adverse Limb Events Among Patients With Peripheral Artery Disease

Accepted for presentation at American College of Cardiology. Findings available upon request. Contact us for more information.

Life Sciences

Do Drug Price Caps Improve Adherence to Treatment? RWE Indicates They Can

The Inflation Reduction Act (IRA) is often described as a pricing policy. In practice, it is a market disruptor. By capping out-of-pocket insulin costs for Medicare beneficiaries, the IRA is changing how patients engage with treatment, how outcomes unfold over time, and how life sciences organizations are expected to demonstrate value.

Hematology, oncology

Outcomes of Inpatient and Outpatient Chimeric Antigen Receptor T-Cell Therapy in Newly Authorized Treatment Centers in the United States

Accepted for presentation at American Society of Hematology (ASH). Findings available upon request. Contact us for more information.

Life Sciences

Inovalon Wins 2025 BioTech Breakthrough Award for HEOR Excellence

For life sciences organizations, the pressure to generate high-quality, real-world evidence has never been greater. Payers expect proof. Regulators expect rigor. And patients expect results that reflect real-world care. To meet today’s market demands, organizations need clear, trusted evidence that speeds access and supports faster, smarter decisions.